Direct-to-Consumer Genetic Testing Devices Market Prognosticated For A Ravishing Growth By 2018-2026

Genetic testing is a type of medical test that determines changes in genes, chromosomes, or proteins. The tests was available only through healthcare professionals such as doctors, nurses, and genetic counselors. However, this trend is gradually shifting towards the customer or consumer. Genetic testing is now offered directly at home, and is called Direct-to-Consumer (DTC) Genetic Testing, which bypasses the mediators or facilitators such as Physicians, Genetic Counselors, and others. The most critical thing about the genetic tests is that these tests are for disease susceptibilities only and cannot be used alone for treatment decisions or other medical interventions. In genetic testing, interpretation is important and is transferred to individual patient, who may not be trained geneticist.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1046

Key players operating in the global direct-to-consumer genetic testing devices market include 23andMe, Pathway Genomics, Color Genomics, Counsyl, Inc., deCode genetics, Inc., Map My Gene, and GenePartner.

Direct-to-Consumer (DTC) Genetic Testing is advantageous for manufacturers as it gives direct access to them to appeal to the customer and maximize their revenue. However, this testing provides easy access to the customer while chances of misinterpretation are really high. The U.S. FDA has kept these tests in “Tier 3” category due to high chances of misinterpretation of direct-to-consumer (DTC) genetic testing. According to FDA, Tier 3 category means that there is no clinical validity or utility of such applications in healthy individuals in the population.

Genetic testing requires patients or healthy individuals to visit trained medical professionals such as doctors, nurses or counselors, in order to get their test interpretations of the result. This process has now become unnecessary or voluntarily with the introduction of direct-to-consumer (DTC) genetic testing devices. This has significantly cut down the cost associated with testing and increasing accessibility of such tests to potential patients.

Increasing awareness about health, especially in developed economies such as U.S., Canada, and U.K. among others, and increasing incidences of chronic diseases such as cancer, Alzheimer’s, and Parkinson’s is majorly contributing to growth of the market. The reasons for this reactiveness varies with geography. For instance, in developed economies such as U.S. and Germany, aging population are more prone to chronic conditions, which include cancer, neurological disorders, and cardiovascular disorders. In 2017, FDA approved direct-to-consumer (DTC) genetic testing for 10 diseases, including Alzheimer’s and Parkinson’s. This has further certified direct-to-consumer (DTC) genetic testing devices for these conditions, which in turn, is expected to increase the use of direct-to-consumer (DTC) genetic tests among patients suffering from the medical conditions.

Limited accessibility to healthcare facilities, mainly in emerging economies such as Brazil, India, and China, is the major reason for low adoption of advanced technologies such as genetic tests. However, introduction of direct-to-consumer (DTC) genetic testing devices is expected to solve this problem as customers can use direct-to-consumer (DTC) genetic testing devices at their home.

Get Access to TOC / Sample Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1046

Manufacturers and regulatory bodies are the essential parts of healthcare ecosystem and cooperation between them is must for any development. Manufacturers drive innovation whereas regulatory authorities insures safety and efficacy of the product or process. However, the direct-to-consumer genetic testing devices market has seen very little cooperation. For instance, 23andMe was started in 2006 and the company started selling its direct-to-consumer (DTC) genetic testing devices in 2007 and was even named ‘Invention of the Year’ by Time magazine in 2008. However, in 2013, FDA ordered 23andMe to discontinue marketing its personal genome service (PGS), as the company had not obtained the legal regulatory approval. The company completely denied the charge and sold their products till 2015. In 2017, the company got first FDA approval for genetic tests for 10 diseases. The hindrance between the manufacturers and regulatory bodies restraints the market growth.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Telehealth Market Anlysis with Inputs form Industry Experts 2018 to 2026

Increasing number of geriatric population, higher incidences of non-communicable disease such as cardiovascular disease, metabolic disorders, Alzheimer’s disease, cancer, diabetics, and other mental health problems which require prolonged treatment would aid in growth of the Telehealth Market in near future. The nature of most non-communicable disease (NCDs) requires well-integrated healthcare system to treat chronic healthcare conditions. Moreover the challenges faced to meet required healthcare professionals, financial and infrastructure resources further can be addressed effectively through telehealth market. The 2016 Physician Supply and Demand Report, released by Association of American Medical College (AAMC), projects the significant physician shortfall in the U.S. between 2014 and 2025, in the range of 61,700 to 94,700.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1020

Increasing prevalence of chronic disease with rising healthcare expenditures and high adoption of health IT infrastructure to support telehealth initiatives are also expected to further boost growth of the telehealth market. Veterans Health Administration (VHA) – the largest integrated health care system in the U.S. uses multiple types of telehealth interventions, which provides both routine and targeted care management services. The 2017 finding from Centers for Medicare and Medicaid Services (CMS), stated that telehealth and telemedicine payments increased by 28% and claims increased by 33% in 2016, over the year 2015.

According to the 2017 U.S. Telemedicine Industry Benchmark Survey conducted among healthcare executives, physicians, nurses, and other healthcare professionals throughout the U.S., it was observed that over half of survey participants noted telemedicine as a top priority or high priority service in their respective organizations. Moreover, study findings also show that telemedicine continues to evolve from a specialty service to a mainstream service. Telehealth is a telecommunication technology, which is also referred to as e-Health or telemedicine. It enables healthcare professionals to evaluate, diagnose, and treat patients in remote locations. According to the 2016 E-health and Telemedicine report by the U.S. Department of Health and Human Services, it revealed that 59 million Americans are living in Health Professional Shortage Area (HPSAs)-rural and urban areas with shortages of primary care providers.

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/1020

According to the 2016 Broadband Progress Report from Federal Communications Commission, around 40% of rural Americans still lack access to broadband Internet. Furthermore, according to the 5G Readiness Survey 2017, by Ericsson AB, 78% respondents of IT decision makers from all major verticals including healthcare have accelerated their plans to incorporate 5G into their IT infrastructure.

Increased adaptation of telehealth will significantly decrease the dependency on hospitals, and enable accessibility to proper healthcare services from home. A report published in March 2017, by NTCA-The Rural Broadband Association stated that, telemedicine could save thousand dollars per year in healthcare and community costs, thereby, reducing significant cost spent on transportation, medical facility, labor wages, and lab cost.

Click To Continue Reading On Telehealth Market

Some of the key players operating in the telehealth market include Koninklijke Philips N.V., Medtronic plc, Tunstall Healthcare Group Ltd, McKesson Corporation, Medvivo Group Ltd., AMD Global Telemedicine, Inc., Vidyo, Inc., Cisco Systems, Inc., Care Innovations, LLC, Honeywell Life Care Solutions, and General Electric Company.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Actinic Keratosis Market Analysis, Growth, Vendors, Shares, Trends, Challenges with Forecast to 2026

Actinic keratosis (AK), referred as solar keratosis is a scaly and crusty growth caused by the damage from exposure to ultraviolet (UV) radiation. These precancerous skin lesions appear on the skin frequently exposed to the artificial sources of UV light, such as tanning machines or the sun. The skin lesions appear elevated, rough textured, and resemble warts. Actinic keratosis reflects abnormal skin cell development, due to DNA damage by short wavelength ultraviolet B (UVB). Individuals working with polycyclic aromatic hydrocarbons (PAHs), such as coal or tar are at a higher risk of getting AKs, as they are mostly exposed to the UV rays and tar. A small percentage of actinic keratosis lesions have the potential to eventually culminate into a type of skin cancer known as squamous cell carcinoma. Prevention of actinic keratosis is important, as the condition can precede cancer or be an early form of skin cancer. Skin biopsy is indicated for the conformation of the diagnosis and to eradicate invasive squamous cell carcinoma for the advanced lesions.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1006

The treatment of actinic keratosis as a part of preventive strategy for the reduction of interrelated disorders, such as non-melanoma skin cancer, squamous cell carcinoma, and basal cell carcinoma is coming to the forefront. According to the U.S. National Library of Medicine, 2015, approximately 60% of squamous cell carcinomas of the skin probably arise from actinic keratosis. Therefore, the rising incidences of skin cancers, such as intra epidermal squamous cell carcinoma, invasive cutaneous squamous cell carcinoma, basal cell carcinoma, and melanoma is expected to augment the market growth. Moreover, the wide presence and easy availability of generic drugs for the treatment for actinic keratosis is expected to boost the market growth. However, lack of medical awareness about the skin condition, available treatments, and delayed diagnosis are some of the factors restraining the global actinic keratosis market.

The global actinic keratosis market is segmented on the basis of treatment type, end user, and geography:,,On the basis of treatment type, the global actinic keratosis treatment market is segmented into:,,Topical treatment,5-fluorouracil (5-FU) Cream,Imiquimod Cream,Diclofenac sodium gel,Ingenol mebutate gel,Others,Surgical Procedures,Cryosurgery,Curettage or Scrapping,Electrocautery,Laser Surgery,Others,Photodynamic therapy,On the basis of end user, the actinic keratosis treatment market is segmented into:,,Hospitals,Dermatologist Clinics,Oncology Centers,Ambulatory Surgical Centers,Others

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1006

The key players operating the actinic keratosis market are DUSA Pharmaceuticals, Inc., Tolmar Pharmaceuticals, Inc., Perrigo Company plc, Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC, Galderma SA, LEO Laboratories, and Apotex. The major manufacturers are committed to developing innovative products that can effectively manage skin conditions, such as actinic keratosis (AKs). For instance, actinic keratosis treatment with Levulan Kerastick and BLU-U photodynamic therapy illuminator with blue light illumination introduced by DUSA Pharmaceuticals, Inc. is indicated for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Oral Biologics Market 2018 Sales, Business Opportunities, Proctuion, Regional Analysis 2026

Oral biologics represent a novel category of drugs, which is gaining traction in the last few decades. Biologic therapeutics has proven to be a highly effective treatment for various chronic ailments, such as diabetes, plaque psoriasis, arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The major concern regarding oral biologics is to protect the protein from degradation and digestion in the gastrointestinal tract. The first products were mostly insulin-related, novel peptides and protein are appearing in the market currently.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/989

For instance, antibodies and their derivatives, particularly human monoclonal antibodies are the most rapidly growing category. Moreover, small interfering RNA, enzymes, cytokines, and various type of peptide drugs are the most studied biological therapeutics. Rapid discoveries of new drug targets, effective engineering processes, and knowledge of the fate of biologics in the human body is resulting in increased number of biologics in the market. Among the therapies, proteins and monoclonal antibodies are expected to fuel the growth of oral biologics market in near future, due to their high selective and potent therapeutic efficacy with limited side effects.

Oral delivery of drugs is the most preferred route of administration by both patients and the manufacturers. Convenience and ease are the major requirements for patients leading to higher medicine adherence. The production cost for the oral dosage is low from other options and offer the greatest adaptability with respect to optimization of drug delivery. The greatest challenge of oral administration of biologic APIs is absorption across the gastrointestinal (GI) tract specifically in the small intestine, which has the highest permeability for the drugs as compared to the large intestine. Large size and polar surface of biomolecules are difficult to diffuse across the epithelial layer. Drug formulations are focusing on the overcoming of various physiochemical challenges by permeation enhancer, enzyme inhibitors, and encapsulation.

Encapsulation is a protective covering that helps to prevent chemicals and enzymatic degradation. For instance, Rani Auto Pill, 2012, is an ordinary robotic capsule delivered in the intestine without exposing the drug to the digestive enzymes. It is incorporated with number of innovations enabling it to navigate through the stomach, which enters small intestine and undergoes transformation to deliver the drug into the intestine, such innovative products are expected to boost growth of market in near future. Currently, insulin buccal sprays, inhaled insulin, nanotechnological systems, phytobiochemicals, and oral insulin are under clinical trials. For instance, Nova Nordisk is bringing its latest oral version GLP-1, type-2 diabetes medication in early 2018 in partnership with Emisphere technologies.

Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/989

The major key players operating the oral biologics market include AstraZeneca plc, Eli Lilly and Co., GlaxoSmithKline plc, Novartis AG, Novo Nordisk, and Rani Therapeutics, LLC. Innovation and collaboration are expected to be the major strategies to combat the oral biologics market.

For instance, Rani Therapeutics announced collaboration with Medimmune in 2016, research and development arm of AstraZeneca globally to evaluate Rani’s novel oral drug delivering platform. This collaboration is expected to conduct feasibility studies of the drug and test biologic molecules in the area of metabolic disease to evaluate the oral delivery of the molecules. The objective of this collaboration is to deliver biologics orally, which is expected to increase the compliance and improve the patient lives globally.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Women’s Health Diagnostic Test Market by Revenue (Value) and Growth Rate 2018-2026

According to the World Health Organization (WHO), around 570,000 women died due to breast cancer in 2015. Moreover, according to the Centers for Disease Control and Prevention (CDC), around 236,968 Women Diagnosed with breast cancer among which around 41,211 women died in 2014. The data indicating a high prevalence of chronic diseases affects lifestyle of women day-by-day. Growing demand for early stage diagnosis of infection/diseases needs new rapid diagnostic tests and imaging system which is expected to fuel the growth of women’s health diagnostic test market in the near future.

Download PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/971

In 2017, Naugatuck Valley Women’s Health Specialists (NVWHS) decided to provide a free informational program for heart health with Boston Heart Diagnostics. Boston Heart diagnostics has anticipating treatment and diagnosis of cardiovascular diseases (CVD), which improves women’s heart health, as CVD is a leading disease in the U.S. This program is expected to create awareness of CVD related diseases among women and also help to improve lifestyle.

In 2017, Mission Hope Cancer Center accredited by the National Accreditation Program for Breast Cancer Centers (NAPBC) joined Dignity Health Central Coast hospitals. In Mission Hope’s cancer care program, breast cancer examination services and facility is expected to be provided to women. Moreover, in 2017, Dignity Health installed 3D imaging technology – Mammography in the central coast. This technology helps in detection of breast cancer before symptomatic stage, which increases 98% survival rate. Thus, this program is expected to create more awareness and early detection of cancer, which in turn is expected to augment the growth of women’s health diagnostic test market.

In 2016, Aeon Clinical Labs launched a RUO women’s health panel test, which is developed by Thermo Fischer Scientific. This test is based on PCR that detects 34 different target include candidiasis, bacterial vaginosis, and sexual transmitted diseases such as gonorrhea, chlamydia, and some others. Aeon is further aiming to expand genetic assays for pharmacogenomics and hereditary cancer in the near future.

Get Exclusive Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/971

According to National Cancer Institute (NCI), in 2016, around 22,280 women diagnosed with ovary cancer and around 14,240 women died due to ovary cancer in U.S. Furthermore, according to Cancer Research UK, in 2014, around 7,378 new cases of ovary cancer and around 55,222 cases of breast cancer were diagnosed in U.K. Moreover, around 20 cases of ovarian cancers are diagnosed every day and is projected to increase by 15% by 2035.

Some of the key players operating in the global women’s health diagnostic test market include Biomerieux SA, F. Hoffmann-LA Roche AG, Becton, Dickinson and Company, Siemens AG, Abbott Laboratories, Hologic, Inc., Koninklijke Philips N.V., Quest Diagnostics Inc., GE Healthcare, and Alere Inc.

Click To Continue Reading On Women’s Health Diagnostic Test Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Cancer Metabolism Based Therapeutics Market Register a Hugh Growth In Healthcare Industry by 2026

According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to pancreatic cancer in the U.S in 2017. As per the ACS, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths in the U.S. Moreover, according to Cancer Research UK, approximately 3,072 new cases were diagnosed with acute myeloid leukemia (AML) and around 2,516 deaths were occurred in 2014.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/961

According to National Cancer Institute, in the U.S, approximately 21,380 (1.3%) new cases and approximately 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.

Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound – Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.

Get Request Sample Copy of Research Report: www.coherentmarketinsights.com/insight/request-sample/961

Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link :https://www.coherentmarketinsights.com/phase-xs,

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Healthcare Cloud Computing Market Outlook and Opportunities in Grooming Regions 2026

Some essential requirements such as security, confidentiality, privacy, traceability of access, reversibility of data, interoperability included in Healthcare data management is possible with the use of cloud computing. The need of legislation of healthcare data compliance policies, rise in interest of load balancing benefits , and the growing of bring –your- own –device (BYOD) strategy at hospitals , are some of the factors leading to the growth of healthcare cloud computing market.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/944

According to Health Information and Management Systems Society (HIMSS), 83% of healthcare organizations are using cloud based apps today, and 53% of healthcare employees are using three or more devices for work. Additionally, cloud computing offers big data sets for radiology images, electronic health records, and genomic data offloading, contributing to the growth of healthcare cloud computing market.

Key industry players operating the healthcare cloud computing market includes ClearData Networks, CareCloud Corporation, AthenaHealth Incorporated, CareStream Health Inc., Dell Incorporated, GNAX Health, IBM Co., Merge Healthcare Incorporated, VMware Incorporated, and Iron Mountain Inc. Healthcare cloud computing market is highly competitive but advantage of cloud computing of being easy to scale up and scale down making use of these services lucrative for companies operating in healthcare cloud computing market.

The global healthcare cloud computing market is segmented by applications, by service model, by deployment model, by pricing model, by component and by region. On the basis of applications, the healthcare cloud computing market is segmented into,,Non –Clinical,,Clinical,,,,,On the basis of service model, healthcare cloud computing market is segmented into,,Information service,,Platform service,,Software service,,,,,On the basis of deployment- model, healthcare cloud computing market is segmented into,,Public- cloud deployment model,,Private- cloud deployment model,,Hybrid -cloud deployment model

Get Discount @ https://www.coherentmarketinsights.com/insight/request-discount/944

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

Key Foresights on Intrathecal Pumps Market Growth and Evolution During 2018-2026

In recent years, management of chronic pain by Intrathecal delivery is gaining importance. Intrathecal pumps allow precisely controlled and sustained release of medication in the human body to get rid of various chronic conditions namely cancer pain and multiple sclerosis. The intrathecal pump and catheters are implanted under the skin surgically to deliver the drug directly into the spinal cord, which offers dramatic pain management.  Besides, these pumps are easy to use, portable, accurate, and also consume very less power. World Health Organization (WHO) has estimated that, 1 out 10 adults are newly identified with chronic pain annually. Thus, there exist a huge potential for intrathecal pumps market.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/935

Drugs used in intrathecal drug delivery pumps consist mainly of opioids, adrenergic agonists, N-methyl-D-aspartate receptor agonists, local anesthetics, and other agents.  As most of the drugs delivered through intrathecal pumps are analgesics, pain management accounts for the largest share in the global intrathecal pumps market followed by spasticity management.

Major changes in the pump therapy for chronic diseases are likely to be observed during the forecast period 2017-2025. Intrathecal pumps are widely used to relive chronic pain in cancer. According to a survey conducted by the International Agency for Research on Cancer (IARC) in 2012, new cases of cancer were estimated to be 14.1 million and mortality rate was approximately 8.2 million. According to a survey conducted by the World Health Organization (WHO) and International Pain Community in 2011, the prevalence of chronic pain in cancer was evaluated around 25% for newly identified patients and greater than 75% for patients with progressive disease.  The demand for advanced intrathecal pumps will extensively upsurge in future with increasing cases of chronic illnesses.

Intrathecal pump device is expected to evolve with several companies working on new technologies that would improve the functioning of programmable pump, internal mechanism, and safety.  In 2014, Food and Drug Administration (FDA) approved the ‘Prometra’ intrathecal pump launched by Flowonix Medical Inc. ‘Prometra’ have various features, such as accurate drug delivery system, dual-gated valve drug distribution, and improved device durability. The other area of interest in the intrathecal space is the development of new drugs that could be delivered to treat specific alignments. For instance, FDA approved number of medications, such as Ziconotide (2004), Spinraza (2016), and probuphine (2016), which have been proven to be safe for intrathecal administration.

Global Intrathecal Pumps Market Taxonomy, On the basis of medication type, the Intrathecal pumps market is segmented into: Baclofen, Hydromorphone, Morphine, Clonidine, Midazolam, Bupivacaine, Others, On the basis of application, the global Intrathecal pumps market is segmented into:Pain Management, Spasticity Management (Continuous muscle contraction)

Get Discount @ https://www.coherentmarketinsights.com/insight/request-discount/935

Some of the key players in intrathecal pumps market are Codman & Shurtleff, Medtronic plc, Arrow International, Medallion Therapeutics, Flowonix, and Tricumed GmbH.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Robotic Rehabilitation and Assistive Technologies Market Size, Share, Trends Analysis and Growth Forecast 2018-2026

Rehabilitation robotics and assistive technologies allow for use of robotic devices for rehabilitation of patients suffering from mobility issues. Robotic rehabilitation and assistive technologies allow for application of robotics in therapeutic procedures to help with recovery a person from various diseases or disabilities such orthopedic traumas, neuromotor disorders, cognitive diseases, strokes and spinal cord injury. Assistive robotics allows people suffering from degenerative motor and/or cognitive abilities to lead an independent life.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/924

Increasing prevalence of disability around the globe is expected to fuel growth of the rehabilitation robotics and assistive technologies market

According to World Health Organization (WHO) 2016, around 1 billion people worldwide suffered from some form of disability, of which around 190 million were unable to carry out daily function independently. Rapid increase in the disabilities due to increasing prevalence of disease such as rheumatoid arthritis, cerebral palsy, spinal cord injury, and other ageing disabilities are expected to increase demand for robotic rehabilitation and assistive technologies. According to WHO 2017, around 47 million people suffered from dementia, with around 10 million new cases reported each year. This creates a highly conducive environment for growth of the robotic rehabilitation and assistive technologies market in the near future. Lack of awareness about new technologies among the populace, especially in emerging economies, and high cost of robotic rehabilitation and assistive technologies is a major factor restraining market growth.

Get Discount @ https://www.coherentmarketinsights.com/insight/request-discount/924

Key players in the market are partnering with healthcare providers to increase market penetration

Key players in robotic rehabilitation and assistive technologies market include Mazor Robotics Ltd., Intuitive Surgical Inc., Accuray, Inc., Health Robotics S.R.L., Kinova, AlterG inc., Ekso Bionics, and Interactive Motion Technologies, Bioxtreme Robotics Rehabilitation, Instead Technologies. In 2016, Ekso Bionics Holdings, Inc., received U.S. Food and Drug Administration (FDA) approval for Ekso GT robotic exoskeleton. This product is used to treat an individual with hemiplegia which occur due to stroke.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Wearable Sensor Market to Have Good Business Opportunities in The Coming Years

Decreasing cost, attractive accessories, and integration with consumer electronic devices are the key factors for boosting the growth of Global Wearable Device market. Additionally, introduction of key players in market such as Google, Amazon, Facebook, Apple, Microsoft, smartphone penetration in sensor technology, the high occurrence of chronic disease related to blood pressure and heart rate, geriatric population with cardiac and neurological disorders, fitness awareness, and reduced digital health-cost are anticipated to significantly drive the growth of global wearable sensors market.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/905

The sensors device processes according to the surrounding environment and it is implemented on the wearable device to monitor body activities, which include, heart rate, body temperature, and blood pressure. Wearable sensors market is expected to show a significant growth over the forecast period, owing to the demand for wearable sensor devices in various applications such as healthcare, lifestyle, fitness, and security.

Moreover, recent advancements in telecommunication, data analysis, sensor manufacturing, and microelectronics are providing opportunities for adoption of wearable sensors in the digital health environment. Additionally, in the healthcare industry, wearable sensors are used for monitoring patient’s conditions. These devices are also used in sports, military, and entertainment. For instance, Apple watch is a wearable device, which includes microphone, accelerometer, and a pulse sensor. Wearable sensors are integrated into garments, watches, eye-glasses, and smartphones, which is fueling the growth of the wearable sensor market.

However, low consumer awareness and safety concerns for security data is a major restraint for growth of wearable sensor market. Moreover, lack of clarity for health communication protocol using wearable device and interoperability issues is expected to hinder the growth of market. Due to low-cost alternatives, intense competition is faced by key manufacturers, which is another factor hindering the growth of global wearable sensors market growth.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/905

Wearable sensors are the devices that collect information about biological and physical properties of body and environment by the sensors present in wearable devices. This information is utilized further to measure the output information of body. Sensors are implemented in wearable devices to track environmental activities, such as temperature and weather information and to track fitness and health activities, such as body temperature, heart rate, stress level, heart pressure, blood pressure, movements, speed, and local temperature. Wearable sensors are used in devices, such as a smart-watch, smart shoes, body-wear, fitness watch, glasses, virtual reality headsets, sleep masks, and jewelry.

The major key players operating global wearable sensor market include Google, Panasonic Corporation, Freescale Semiconductor, Fossil Groups, InvenSense, Facebook, Amazon, Apple, Microsoft, Infineon Technologies AG, ST Microelectronics, and Analog Devices, Inc. These players are focused on developing business through strategies of merging-acquisition and product development to enhance the global growth. For instance, Facebook acquired Basis Science in March 2015, which specializes wearable sensor technology in wrist-watches. Moreover, Fossil Groups acquired Misfit in November 2015, to enhance their growth in global market.

Get full report: https://www.coherentmarketinsights.com/ongoing-insight/wearable-sensor-market-905

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]